# Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

> **NCT00101192** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 76 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00101192
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2011-07
- **Final completion:** —
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2014-03-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101192, "Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00101192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*